217 related articles for article (PubMed ID: 28341757)
1. Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.
Levin LI; Breen EC; Birmann BM; Batista JL; Magpantay LI; Li Y; Ambinder RF; Mueller NE; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1114-1123. PubMed ID: 28341757
[No Abstract] [Full Text] [Related]
2. Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma.
Hollander P; Ginman B; Molin D; Enblad G; Amini RM; Glimelius I
Immunobiology; 2020 Jan; 225(1):151872. PubMed ID: 31787352
[TBL] [Abstract][Full Text] [Related]
3. Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma.
Levin LI; Chang ET; Ambinder RF; Lennette ET; Rubertone MV; Mann RB; Borowitz M; Weir EG; Abbondanzo SL; Mueller NE
Blood; 2012 Nov; 120(18):3750-5. PubMed ID: 22972983
[TBL] [Abstract][Full Text] [Related]
4. Classical Hodgkin Lymphoma with Positive Epstein-Barr Virus Status is Associated with More FOXP3 Regulatory T Cells.
Pavlovic A; Glavina Durdov M; Capkun V; Jakelic Pitesa J; Bozic Sakic M
Med Sci Monit; 2016 Jul; 22():2340-6. PubMed ID: 27377121
[TBL] [Abstract][Full Text] [Related]
5. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma.
Breen EC; Hussain SK; Magpantay L; Jacobson LP; Detels R; Rabkin CS; Kaslow RA; Variakojis D; Bream JH; Rinaldo CR; Ambinder RF; Martinez-Maza O
Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1303-14. PubMed ID: 21527584
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the antibody response to the EBV proteome in EBV-associated classical Hodgkin lymphoma.
Liu Z; Jarrett RF; Hjalgrim H; Proietti C; Chang ET; Smedby KE; Yu KJ; Lake A; Troy S; McAulay KA; Pfeiffer RM; Adami HO; Glimelius B; Melbye M; Hildesheim A; Doolan DL; Coghill AE
Int J Cancer; 2020 Aug; 147(3):608-618. PubMed ID: 31618442
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes.
Levin LI; Ramirez CM; Liao EL; Guo H; Kim BK; Marrogi AJ; Magpantay LI; Breen EC; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2023 Feb; 32(2):233-241. PubMed ID: 36409490
[TBL] [Abstract][Full Text] [Related]
8. A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly.
Wang E; Papavassiliou P; Sebastian S
Pathol Res Pract; 2012 Jun; 208(6):363-7. PubMed ID: 22572037
[TBL] [Abstract][Full Text] [Related]
9. The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma.
Jones K; Wockner L; Brennan RM; Keane C; Chattopadhyay PK; Roederer M; Price DA; Cole DK; Hassan B; Beck K; Gottlieb D; Ritchie DS; Seymour JF; Vari F; Crooks P; Burrows SR; Gandhi MK
Clin Exp Immunol; 2016 Feb; 183(2):206-20. PubMed ID: 26422112
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC.
Plattel WJ; Alsada ZN; van Imhoff GW; Diepstra A; van den Berg A; Visser L
Br J Haematol; 2016 Dec; 175(5):868-875. PubMed ID: 27610595
[TBL] [Abstract][Full Text] [Related]
11. Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a clinicopathological study of 14 Epstein-Barr virus-positive cases.
Elsayed AA; Satou A; Eladl AE; Kato S; Nakamura S; Asano N
Histopathology; 2017 Mar; 70(4):579-594. PubMed ID: 27735994
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups.
Urayama KY; Jarrett RF; Hjalgrim H; Diepstra A; Kamatani Y; Chabrier A; Gaborieau V; Boland A; Nieters A; Becker N; Foretova L; Benavente Y; Maynadié M; Staines A; Shield L; Lake A; Montgomery D; Taylor M; Smedby KE; Amini RM; Adami HO; Glimelius B; Feenstra B; Nolte IM; Visser L; van Imhoff GW; Lightfoot T; Cocco P; Kiemeney L; Vermeulen SH; Holcatova I; Vatten L; Macfarlane GJ; Thomson P; Conway DI; Benhamou S; Agudo A; Healy CM; Overvad K; Tjønneland A; Melin B; Canzian F; Khaw KT; Travis RC; Peeters PH; González CA; Quirós JR; Sánchez MJ; Huerta JM; Ardanaz E; Dorronsoro M; Clavel-Chapelon F; Bueno-de-Mesquita HB; Riboli E; Roman E; Boffetta P; de Sanjosé S; Zelenika D; Melbye M; van den Berg A; Lathrop M; Brennan P; McKay JD
J Natl Cancer Inst; 2012 Feb; 104(3):240-53. PubMed ID: 22286212
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases.
Haque T; Chaggar T; Schafers J; Atkinson C; McAulay KA; Crawford DH
J Med Virol; 2011 Feb; 83(2):311-6. PubMed ID: 21181928
[TBL] [Abstract][Full Text] [Related]
14. Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis.
Vener C; Guffanti A; Pomati M; Colombi M; Alietti A; La Targia ML; Bamonti-Catena F; Baldini L
Leuk Lymphoma; 2000 Apr; 37(3-4):333-9. PubMed ID: 10752984
[TBL] [Abstract][Full Text] [Related]
15. Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.
Ghesquières H; Maurer MJ; Casasnovas O; Ansell SM; Larrabee BR; Lech-Maranda E; Novak AJ; Borrel AL; Slager SL; Brice P; Allmer C; Brion A; Ziesmer SC; Morschhauser F; Habermann TM; Gaillard I; Link BK; Stamatoullas A; Fermé C; Dogan A; Macon WR; Audouin J; Cerhan JR; Salles G
Cytokine; 2013 Nov; 64(2):523-31. PubMed ID: 24008079
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus (EBV) positive classical Hodgkin lymphoma of Iraqi children: an immunophenotypic and molecular characterization of Hodgkin/Reed-Sternberg cells.
Di Napoli A; Al-Jadiri MF; Talerico C; Duranti E; Pilozzi E; Trivedi P; Anastasiadou E; Alsaadawi AR; Al-Darraji AF; Al-Hadad SA; Testi AM; Uccini S; Ruco L
Pediatr Blood Cancer; 2013 Dec; 60(12):2068-72. PubMed ID: 24000236
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of CD20 expression and Epstein-Barr virus (EBV) association in classical Hodgkin lymphoma in Japan: a clinicopathologic study.
Elsayed AA; Asano N; Ohshima K; Izutsu K; Kinoshita T; Nakamura S
Pathol Int; 2014 Jul; 64(7):336-45. PubMed ID: 25047504
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Epstein-Barr virus strains and variants in classical Hodgkin's lymphoma by laser microdissection.
García-Cosío M; Santón A; Martín P; Reguero ME; Cristóbal E; Bellas C
Histol Histopathol; 2008 Feb; 23(2):209-17. PubMed ID: 17999377
[TBL] [Abstract][Full Text] [Related]
19. The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis.
Carbone A; Gloghini A; Caruso A; De Paoli P; Dolcetti R
Int J Cancer; 2017 Mar; 140(6):1233-1245. PubMed ID: 27750386
[TBL] [Abstract][Full Text] [Related]
20. A Novel Risk Locus at 6p21.3 for Epstein-Barr Virus-Positive Hodgkin Lymphoma.
Delahaye-Sourdeix M; Urayama KY; Gaborieau V; Veenstra R; Foll M; Chabrier A; Benavente Y; Nieters A; Becker N; Foretova L; Maynadié M; Staines A; Smedby KE; Glimelius I; Lightfoot T; Cocco P; Galan P; Vatten LJ; Duell EJ; Kiemeney L; Roman E; de Sanjosé S; Lathrop M; Melbye M; Brennan P; Diepstra A; van den Berg A; Hjalgrim H; Jarrett RF; McKay JD
Cancer Epidemiol Biomarkers Prev; 2015 Dec; 24(12):1838-43. PubMed ID: 26404960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
